Video

Options for Iron Chelation Therapy

Iron chelation therapy is very effective at putting a patient in a negative iron balance, even with continued transfusions, as long as the patient can tolerate therapy, says Morey Blinder, MD.

Several chelating agents are available. Deferoxamine, which is given intravenously or subcutaneously, is the oldest chelating agent and deferasirox, or Exjade, or a more modern therapy. Although effective, Exjade was associated with nausea, vomiting, and diarrhea, in some patients. The latest advance is a new formulation of deferasirox, called Jadenu, which has recently become available.

The greatest concern with deferasirox, in the form of Exjade, says Blinder, is adherence to therapy. Jadenu is much better tolerated in terms of gastrointestinal toxicities, and also is much easier for the patient to take. Blinder says that he is switching his patients from Exjade to the newer formulation. The response from patients has been a positive one, which Blinder finds very gratifying.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.